SCHEMBL19855058

SCHEMBL19855058

C=CC(=O)N(C)CCCc1ccc(-c2ccc(CCC3CCC(CCCCC)CC3)cc2F)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 4/20 0.45
▸ RARA P10276 1/20 0.36
▸ RARG P13631 1/20 0.36
▸ THRB P10828 7/20 0.35
▸ THRA P10827 6/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ S1PR3 Q99500 3/20 0.33
▸ S1PR1 P21453 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19855004 0.92 RARB (0.41) RARBCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL19855003 0.90 RARB (0.43) RARBRARARARGTHRBTHRA
SCHEMBL19854428 0.90 RARB (0.56) RARBRARARARGTHRBTHRA
SCHEMBL19854624 0.89 RARB (0.42) RARBRARARARGCYP3A4CYP2C9
SCHEMBL19854629 0.89 RARB (0.42) RARBRARARARGCYP3A4CYP2C9
SCHEMBL19855109 0.89 RARB (0.55) RARBRARARARGTHRBTHRA
SCHEMBL19855110 0.89 RARB (0.55) RARBRARARARGTHRBTHRA
SCHEMBL20370502 0.88 RARB (0.41) RARBRARARARGCYP3A4CYP2D6
SCHEMBL19856065 0.88 RARB (0.41) RARBTHRBS1PR3S1PR1
SCHEMBL19854045 0.87 RARB (0.38) RARBRARARARGCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 RARB 1437/4885RARA 1599/4885RARG 598/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 RARB 1437/4885RARA 1599/4885RARG 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback